Drug Profile
Influenza A virus H1N1 vaccine - Sanofi
Alternative Names: Humenza; Inactivated H1N1 vaccine - Sanofi; Influenza A (H1N1) 2009 monovalent vaccine, adjuvanted - Sanofi; Influenza A (H1N1) 2009 monovalent vaccine, non-adjuvanted - Sanofi; Influenza A(H1N1) monovalent vaccine - Sanofi; Pandemic influenza vaccine (H1N1) split virion; Panenza; Swine flu vaccine - SanofiLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator sanofi pasteur
- Developer Sanofi; sanofi pasteur
- Class Influenza A virus H1N1 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza A virus H1N1 subtype
Most Recent Events
- 02 Aug 2019 Influenza A virus H1N1 vaccine is not yet available in Brazil, Germany, Luxembourg, Tunisia, Turkey (IM)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-A-virus-H1N1-subtype (Prevention) in Brazil (IM, Injection)
- 06 Mar 2014 Discontinued - Registered for Influenza-A virus H1N1 subtype in European Union (IM, adjuvanted)